Evidence map›Paper›PMID 40105785›Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025

Biventricular vs. right ventricular pacing devices in patients anticipated to require frequent ventricular pacing (BioPace).

Reinhard C Funck, Hans-Helge Müller, Maurizio Lunati, Luc De Roy, Norbert Klein, Eckhard Meisel, Goran Milasinovic, Mark D Carlson, Michael Wittenberg, Gerhard Hindricks and 1 more

Erratum issued Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyComparative Study
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00187278 (Biventricular Pacing for Atrioventricular Block in Left Ventricular Dysfunction to Prevent Cardiac Desynchronization), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00187278 nacompletednot on this map

Biventricular Pacing for Atrioventricular Block in Left Ventricular Dysfunction to Prevent Cardiac Desynchronization

TypeinterventionalSponsorAbbott Medical DevicesRan2003 to 2014Enrolled1,833ConditionsAtrioventricular Block, Ventricular DysfunctionArmsBiventricular Pacing, RV Pacing
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Conduction system pacing: what emerging evidence and what indications?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. How harmful is right ventricular pacing? The question revived by the BioPace trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Reinhard C FunckKlinik für Innere Medizin - Kardiologie, Philipps-Universität Marburg, Baldingerstr, Marburg 35033, Germany.ORCID 0000-0002-4810-7427
Hans-Helge MüllerInstitut für Medizinische Bioinformatik und Biostatistik, Philipps-Universität Marburg, Hans-Meerwein-Str. 6, Marburg 35043, Germany.ORCID 0000-0002-1536-9551
Maurizio LunatiCardiologia 3 - Elettrofisiologia, Ospedale Niguarda, Piazza Ospedale Maggiore 3, Milano 20162, Italy.
Luc De RoyCardiology Department, CHU Namur, Ave G. Therasse 1-8, Yvoir 5530, Belgium.
Norbert KleinDepartment of Cardiology, Klinikum St. Georg gGmbH, Delitzscher Str. 141, Leipzig 04129, Germany.ORCID 0000-0003-1358-1847
Eckhard MeiselPraxisklinik HerzKreislauf am WASA-Platz, August-Bebel-Str. 33, Dresden 01219, Germany.ORCID 0009-0009-5135-1496
Goran MilasinovicPacemaker Clinic, Klinicki Centar Srbije, Beograd 11000, Serbia.ORCID 0000-0002-5678-8744
Mark D CarlsonAbbott Cardiac Arrhythmias and Heart Failure, 15900 Valley View Court, Sylmar, CA, USA.ORCID 0000-0002-4354-2577
Michael WittenbergCoordinating Center for Clinical Trials, Philipps-University Marburg, Karl-von-Frisch-Str. 4, Marburg 35043, Germany.ORCID 0000-0003-4526-1856
Gerhard HindricksDepartment of Cardiology, Angiology and Intensive Care Medicine, Campus Charité Mitte, Charitéplatz 1, Berlin 10117, Germany.ORCID 0000-0002-0132-0773
Jean-Jacques BlancDepartment of Cardiology, Brest University Hospital, Boulevard Tanguy Prigent, Brest 29609, France.

Funding

Abbott
6 · The paper itself

Abstract

aimsRight ventricular (RV) pacing may promote left ventricular (LV) dysfunction. Particularly in patients with preserved LV ejection fraction (LVEF), narrow QRS, and anticipated high ventricular pacing burden (HVPB), evidence is missing that biventricular (BiV) pacing can improve clinical outcome. We therefore evaluated whether implantation of a BiV pacing device (BiVPD) compared with a RV pacing device (RVPD) may improve clinical outcome in predominantly this kind of patients. METHODS AND

resultsIn the Biventricular Pacing for atrioventricular Block to Prevent Cardiac Desynchronization (BioPace) trial [multicentre, single-blinded (patients), randomized, parallel group], patients were equally allocated to either receive a BiVPD or a RVPD. Co-primary endpoints were (i) the composite of time to death or first heart failure hospitalization and (ii) survival time. We analysed 1810 randomized patients (median age: 73.5 years; female sex: 31.7%; mean LVEF 55.4%; mean QRS 118.4 ms), 902 to BiV and 908 to RV pacing. During mean follow-up of 68.8 months, the difference in the primary composite endpoint between both groups [346 vs. 363 events, hazard ratio (HR) 0.878; 95% confidence interval (CI) 0.756-1.020; P = 0.0882) or in mortality (305 vs. 307 deaths, HR 0.926; 95% CI 0.789-1.088; P = 0.3492) was smaller than 20%.

conclusionIn patients, predominantly with preserved LVEF, narrow QRS, and HVPB, superiority of implanting BiVPDs compared with RVPDs could not be proven. Right ventricular pacing may be less harmful for this kind of patients than often suggested and primary BiV pacing does not clearly improve their clinical outcome. CLINICAL

trial registrationRegistered in ClinicalTrials.gov, number NCT00187278 (https://clinicaltrials.gov/ct2/show/study/NCT00187278).

Indexed as

Atrioventricular BlockCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesHeart FailureHeart VentriclesVentricular Function, LeftVentricular Function, RightAgedAged, 80 and overFemaleHumansMaleMiddle AgedRisk FactorsSingle-Blind MethodStroke VolumeBiventricular pacingCardiac pacingHeart failureMortalityPacing-induced cardiomyopathyRight ventricular pacing

Identifiers

PMID40105785
PMCPMC11921422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.